Use of molsidomine or one of its pharmaceutically acceptable salts in the form of a solid oral release composition maintained effective for 24 hours, for the manufacture of a medicament intended to prevent or attenuate the development of atherosclerosis, where said composition has an index in vitro solution, measured spectrophotometrically at 286 or 311 nm according to the method described in the European Pharmacopoeia, 3rd edition (or USP XXIV) at 50 rpm in 500 ml of a 0.1 N HCl medium, at 37 ° C, of: - 15 to 25% molsidomine released after 1 hour - 20 to 35% molsidomin released after 2 hours - from 50 to 65% of molsidomine released after 6 hours - from 75 to 95% of molsidomine released after 12 hours ->； 85% of molsidomine released after 18 hours ->； 90% of molsidomine released after 24 hours, with the molsidomine plasma peak obtained in vivo within 2.5 to 5 hours, preferably in 3 to 4 hours, following administration of said form and having a value between 25 and 40 ng / ml of plasma , where the solid oral composition mentioned above carries, as a dosage unit intended to be administered daily, between 14 and 24 mg of molsidomine, and where the treatment is of a duration of at least 6 months.Utilización de la molsidomina o de una de sus sales farmacéuticamente aceptables en forma de una composición oral sólida de liberación mantenida eficaz durante 24 horas, para la fabricación de un medicamento destinado a prevenir o atenuar el desarrollo de la aterosclerosis, donde dicha composición presenta un índice de disolución in vitro, medido espectrofotométricamente a 286 ó 311 nm según el método descrito en la Farmacopea Europea, 3ª edición (o U.S.P. XXIV) a 50 r.p.m. en 500 ml de un medio de HCl 0,1 N, a 37°C, de : - de un 15 a un 25% de molsidomina liberada después de 1 hora - de un 20 a un 35% de molsidomina liberada después de 2 horas - de un 50 a un 65% de molsidomina liberada después de 6 horas - de un 75 a un 95% de molsidomina liberada después de 12 horas - >
